GlassScriptPhysician profile
Elliot Sultanik
NPI 1508220583
$6,777.43
in general payments reported to CMS, 2019-2025
32 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 83% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $907 · 2023: $2,243 · 2024: $2,008 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $743.31 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $742.78 | 2022-2025 | |
| Amgen INC. | $615.22 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $533.48 | 2022-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $445.17 | 2023-2025 | Onyx Frontier, Symplicity G3, Mycarelink |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.90 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $372.01 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $362.48 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $351.89 | 2022-2025 | Amvuttra, Onpattro |
| Boston Scientific Corporation | $245.79 | 2021-2024 | Watchman, Resonate El Icd Vr, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $234.95 | 2022-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $231.20 | 2022-2024 | Xarelto |
| Scpharmaceuticals INC. | $197.07 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $197.00 | 2023-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $172.18 | 2023-2025 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $126.11 | 2022-2024 | |
| Cardiovascular Systems INC. | $117.26 | 2022 | |
| Abbott Laboratories | $94.50 | 2024 | Mitraclip |
| Kiniksa Pharmaceuticals, LTD. | $77.84 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $74.79 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $63.24 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $61.28 | 2024 | |
| Merck Sharp & Dohme LLC | $60.22 | 2022-2024 | Verquvo |
| Abiomed | $52.83 | 2023-2024 | Impella |
| Philips North America LLC | $49.27 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Heartflow, INC. | $35.36 | 2025 | |
| Cardiva Medical, INC. | $29.38 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Vital Connect, INC | $22.46 | 2023 | Vitalpatch Rtm |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.31 | 2024 | Lifevest |
| Irhythm Technologies, INC. | $17.73 | 2024 | Zio Monitor, Zio Xt Patch |
| Amarin Pharma, INC. | $16.08 | 2023 | |
| Chiesi USA, INC. | $14.34 | 2023 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Sultanik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.